Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

PhenomeX Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

PhenomeX şirketinin kazançları yıllık ortalama -37.4% oranında azalırken, Life Sciences sektörünün kazançları yıllık 13.6% oranında artan oldu. Gelirler yıllık ortalama 8.8% oranında artan oldu.

Anahtar bilgiler

-37.4%

Kazanç büyüme oranı

65.0%

EPS büyüme oranı

Life Sciences Sektör Büyümesi	21.5%
Gelir büyüme oranı	8.8%
Özkaynak getirisi	-111.9%
Net Marj	-173.4%
Son Kazanç Güncellemesi	30 Jun 2023

Yakın geçmiş performans güncellemeleri

Recent updates

Analyst Forecasts Just Became More Bearish On PhenomeX Inc. (NASDAQ:CELL)

May 16

PhenomeX Inc.'s (NASDAQ:CELL) Subdued P/S Might Signal An Opportunity

Apr 17

Analysts Just Made A Major Revision To Their Berkeley Lights, Inc. (NASDAQ:BLI) Revenue Forecasts

Aug 15

Berkeley Lights: Optofluidic Technology Presents Strong Upside, May Redefine Therapeutic Development

Jun 09

Berkeley Lights Q1 2021 Earnings Preview

May 10

Gelir ve Gider Dağılımı

PhenomeX nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:CELL Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 23	72	-125	110	35
31 Mar 23	77	-100	104	44
31 Dec 22	79	-98	95	53
30 Sep 22	84	-86	82	61
30 Jun 22	87	-85	75	68
31 Mar 22	87	-78	72	63
31 Dec 21	85	-72	69	59
30 Sep 21	84	-66	63	57
30 Jun 21	78	-54	55	51
31 Mar 21	69	-50	45	49
31 Dec 20	64	-43	38	47
30 Sep 20	59	-35	31	43
30 Jun 20	57	-32	26	43
31 Mar 20	58	-26	24	41
31 Dec 19	57	-21	22	38
31 Dec 18	31	-27	15	29

Kaliteli Kazançlar: CELL şu anda kârlı değil.

Büyüyen Kar Marjı: CELL şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: CELL kârlı değildir ve zararlar son 5 yılda yılda 37.4% oranında artmıştır.

Büyüme Hızlandırma: CELL 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: CELL kârlı olmadığından, geçmiş yıl kazanç büyümesinin Life Sciences sektörüyle ( -11.3% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: CELL hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -111.91% ) sahiptir.

PhenomeX Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

PhenomeX Inc. to Report Q2, 2023 Results on Aug 14, 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS and revenues miss analyst expectations

Berkeley Lights, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Third quarter 2022 earnings: EPS misses analyst expectations

Recent updates

Bruker Cellular Analysis, Inc. Files Form 15

Phenomex Announces Opto Memory B Discovery Human Workflow on the Beacon®? Optofluidic Platform

PhenomeX Inc. Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows

Phenomex Unveils Meteor Chips for Quantitative Bulk Analysis on the Isospark™ Platform to Revolutionize High Throughput Multiplexed Hands-Free Proteomics

Consensus EPS estimates upgraded to US$1.13 loss

Consensus EPS estimates fall by 22%

Price target decreased by 29% to US$4.00

Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire all of the outstanding shares of PhenomeX Inc. (NasdaqGS:CELL).

New major risk - Share price stability

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

PhenomeX Inc. to Report Q2, 2023 Results on Aug 14, 2023

PhenomeX Inc. Announces Lifting of the Stay in AbCellera Patent Infringement Case

PhenomeX Inc.(NasdaqGS:CELL) dropped from Russell Small Cap Comp Value Index

PhenomeX Receives a Notice from Nasdaq Regarding Minimum Bid Price Rule

PhenomeX Inc. Launches Beacon Quest™? Optofluidic System with Opto®? T Cell Profiling Workflows

Price target decreased by 31% to US$5.67

Consensus revenue estimates decrease by 16%, EPS upgraded

PhenomeX Inc. Launches Beacon Select Optofluidic System with Opto B Discovery Workflows

Analyst Forecasts Just Became More Bearish On PhenomeX Inc. (NASDAQ:CELL)

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

PhenomeX Inc. Provides Earning Guidance for the Full Year of 2023

PhenomeX Inc.'s (NASDAQ:CELL) Subdued P/S Might Signal An Opportunity

Full year 2022 earnings: EPS and revenues miss analyst expectations

Berkeley Lights, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Berkeley Lights, Inc. Provides Preliminary Revenue Guidance for the Year Ended December 31, 2022

Berkeley Lights, Inc. (NasdaqGS:BLI) announced a definitive agreement to acquire IsoPlexis Corporation (NasdaqGS:ISO) from a group of shareholders for $56.3 million.

CEO & Director notifies of intention to sell stock

President of Global Operations notifies of intention to sell stock

Berkeley Lights Accelerating Antibody Discovery with Launch of Rabbit Memory B Cell Workflow

High number of new directors

Third quarter 2022 earnings: EPS misses analyst expectations

Berkeley Lights, Inc. Provides Revenue Guidance for the Year 2022

Berkeley Lights, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Berkeley Lights, Inc. Announces Appointment of Scott Chaplin as Chief Legal Officer and Corporate Secretary

CEO & Director notifies of intention to sell stock

President of Global Operations notifies of intention to sell stock

Consensus revenue estimates fall by 17%

Analysts Just Made A Major Revision To Their Berkeley Lights, Inc. (NASDAQ:BLI) Revenue Forecasts

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Berkeley Lights, Inc. Provides Revenue Guidance for the Full Year 2022

Berkeley Lights, Inc. and the Jaime Leandro Foundation Announce the Discovery, Functional Characterization, and Recovery of A Patient-Derived T Cell Receptor Sequence Against A Cancer Neoantigen

Berkeley Lights, Inc. Announces Appointment of Dr. Rolando Brawer as Executive Vice President, Strategy & Corporate Development

Berkeley Lights Inc. Announces Mehul Joshi as New Chief Financial Officer

Mehul Joshi joins Berkeley Lights as CFO

Berkeley Lights, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Insider notifies of intention to sell stock

First quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to US$16.80

High number of new directors

Berkeley Lights, Inc., Annual General Meeting, May 26, 2022

Berkeley Lights Announces Appointment of Lucas S. Vitale as Chief Human Resources Officer

Insider recently bought US$502k worth of stock

Berkeley Lights, Inc. Releases Upgrade to Its Software Suite for Beacon and Lightning Platforms

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Berkeley Lights, Inc. Reiterates Revenue Guidance for Full Year 2022

Price target decreased to US$30.40

Berkeley Lights, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Berkeley Lights, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case

ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Berkeley Lights, Inc

High number of new directors

Berkeley Lights, Inc. Provides Revenue Guidance for Full Year of 2021 and 2022

Berkeley Lights, Inc. to Showcase its Optofluidic Discovery Technology At 2021 Antibody Engineering & Therapeutics Conference

Berkeley Lights Grows Revenue But Operating Losses Mount

Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Berkeley Lights, Inc

Independent Chairman of the Board recently bought US$500k worth of stock

Are Investors Undervaluing Berkeley Lights, Inc. (NASDAQ:BLI) By 49%?

Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.16 loss in 3Q 2020)

Berkeley Lights: Short Seller Report Raises A Few Legitimate Questions